Skip to main content
Download PDF

Correction: Repurposed agents in the Alzheimer’s disease drug development pipeline

Alzheimer's Research & Therapy volume 15, Article number: 139 (2023) Cite this article

The Original Article was published on 17 August 2020

Correction: Alzheimers Res Ther 12, 98 (2020)

https://doi.org/10.1186/s13195-020-00662-x

Following the publication of the original article [1], the authors would like to correct the three occurrences of Dr. Jeffrey Cummings’s initial in Competing interests section from "JL" to "JC”.

The original article [1] has been updated.

Reference

  1. Bauzon J, Lee G, Cummings J. Repurposed agents in the Alzheimer’s disease drug development pipeline. Alzheimers Res Ther. 2020;12:98. https://doi.org/10.1186/s13195-020-00662-x.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Medicine, University of Nevada, Las Vegas (UNLV), Las Vegas, NV, 89154, USA

    Justin Bauzon

  2. Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, 89106, USA

    Garam Lee & Jeffrey Cummings

  3. Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada, Las Vegas (UNLV), Las Vegas, NV, 89154, USA

    Jeffrey Cummings

Authors
  1. Justin Bauzon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Garam Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jeffrey Cummings
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey Cummings.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bauzon, J., Lee, G. & Cummings, J. Correction: Repurposed agents in the Alzheimer’s disease drug development pipeline. Alz Res Therapy 15, 139 (2023). https://doi.org/10.1186/s13195-023-01284-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s13195-023-01284-9

Alzheimer's Research & Therapy

ISSN: 1758-9193